GLP-1 side effects and weight loss claims: what holds up?

What did @maggie.gusman actually say?

Maggie filmed herself struggling to finish what appears to be a meal, describing intense nausea and a suppressed appetite. She says her "brain and stomach" are fighting her, that she's "gagging," and that she can't finish what is also her first meal of the day. She closes by mentioning she's on "Cagory" and "Dintyde," which appear to be references to cagrilintide (or possibly cagrisema, a combo of cagrilintide and semaglutide) and tirzepatide. She invites followers to ask for more info.

The transcript is garbled, almost certainly because of auto-captions or transcription error, so some interpretation is required. She is not making a formal medical claim, but she is implicitly suggesting these medications are responsible for her inability to eat, and she's doing so in a way that frames extreme appetite suppression as a desirable outcome.

Does the science back this up?

Yes, appetite suppression this intense is documented with both tirzepatide and cagrilintide combinations, though the degree she's describing raises questions about tolerability rather than efficacy. The nausea and appetite suppression are real, but the framing matters.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, consistently reduces caloric intake in clinical trials. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed up to 22.5% mean body weight reduction, with nausea and vomiting among the most common adverse events, affecting roughly 30-40% of participants at higher doses.

Cagrilintide is an amylin analogue. In combination with semaglutide (the combo called CagriSema), early phase trials (Enebo et al., 2021, The Lancet) showed additive appetite suppression beyond either drug alone. If she is on both cagrilintide-based treatment and tirzepatide simultaneously, that is a combination with very limited safety data in real-world populations and is not a standard clinical protocol.

What did they get wrong (or right)?

She's right that these medications suppress appetite powerfully, sometimes uncomfortably so. That part is accurate. GLP-1 and amylin-based treatments slow gastric emptying, reduce hunger signals, and can make finishing a normal meal genuinely difficult. That is not a myth.

What's worth flagging is the framing. Showing yourself gagging through a meal while describing it as part of staying "thin" positions extreme medication-induced nausea as aspirational. Clinically, this level of intolerance at mealtime is a signal to talk to a prescriber, not a badge of efficacy. Dose adjustments exist for a reason.

Also worth noting: stacking tirzepatide with cagrilintide or cagrisema is not a standard or widely studied protocol. The REDEFINE trials for cagrisema are still ongoing. Presenting this combination casually to 17,000 viewers without any safety context is the actual problem here, not the pharmacology itself.

What should you actually know?

Nausea on GLP-1 or amylin-based medications is common and usually dose-dependent. It typically peaks early in treatment and improves over time. But if you cannot finish your first meal of the day and you feel like you're "going to go out," that is a conversation to have with your prescriber, not a TikTok moment.

The medications she references are real, but the combination she describes is on the frontier of clinical investigation, not standard of care. Cagrisema is still in Phase 3 trials as of 2024. Tirzepatide is FDA-approved under the brand names Mounjaro and Zepbound. These are not interchangeable, and their combined use carries unknowns around cardiovascular, gastrointestinal, and metabolic effects that have not been fully characterized in large populations.

If appetite suppression reaches the point where adequate nutrition becomes difficult, that is a side effect requiring management, not proof the medication is working harder. Muscle loss, nutrient deficiency, and disordered eating patterns are real downstream risks when intake is chronically too low.

The bottom line

Maggie is experiencing documented, pharmacologically plausible side effects. She is not making up the nausea or the appetite suppression. But the combination she's on is not well-studied, and presenting it to a large audience as a weight-maintenance strategy without clinical context does real harm. The science supports the mechanism. It does not support the framing.